PharmiWeb Recruiter Blog

Posts by

Editor

Theragenix

TherageniX and University of Nottingham Awarded £995K Innovate UK Grant to Develop Powdered Gene Therapy for Bone Regeneration

  • Novel non-viral gene delivery platform to help advance tissue repair following orthopaedic surgery
  • Funding from Innovate UK’s Transforming Medicines Manufacturing programme supporting innovative technologies for intracellular drug delivery

London, UK, and Nottingham, UK, 31 August 2023: TherageniX, a University of Nottingham spin out pioneering a dry powder gene therapy formulation for bone graft augmentation, and its collaborator, the University of Nottingham, have been awarded a £995,000 grant from Innovate UK, the UK’s innovation agency. The funding will support the development of the Company’s gene therapy in a powder, a non-viral gene delivery system to improve tissue regeneration following surgery. TherageniX will initially focus on orthopaedic applications, with the aim of improving the outcomes for patients undergoing bone grafting procedures.

Read more
Bayer

Bayer to invest EUR 220 million in new R&D facility at its Monheim site

Largest single investment in Crop Protection in Germany for 40 years / Focus on Environmental and Human Safety / State-of-the-art lab building and greenhouse / 5 floor main building; 28,000 m2 gross floor area / R&D facility offers space for 200 employees / Early safety screens and A.I. help design the next generation of Crop Protection

Read more
BioMed X

BioMed X Institute Starts Its First Research Project with Sanofi on Artificial Intelligence for Drug Development

  • Powered by Sanofi, a new BioMed X research team will develop a computational platform designed to accelerate drug development.

Heidelberg, June 29, 2023. BioMed X, a German independent research institute, announces the start of its first research project in collaboration with Sanofi: “Next Generation Virtual Patient Engine for Clinical Translation of Drug Candidates” (VPE). The end goal of this research project is to develop a versatile computational platform that can predict the efficacy of first- or best-in-class drug candidates in virtual patient populations at unprecedented accuracy, thereby addressing one of the most critical bottlenecks of the pharmaceutical industry today: a 90% failure rate of new drug candidates during clinical development.

Read more
Caidya

Caidya Wins CRO Leadership Award for Overall Capabilities

Caidya was honored at the CRO Leadership Awards held in Boston, MA at the end of June for their win in the Overall Capabilities category. The award is a recognition of Caidya’s outstanding global capabilities and the tireless work that the team does daily to fulfill our vision to ensure potential therapies have the best opportunity to reach patients in need.

Read more
Johnson & Johnson

Johnson & Johnson Announces Final Results of Exchange Offer and Finalizes Separation of Kenvue Inc.

NEW BRUNSWICK, N.J., August 23, 2023 – Johnson & Johnson (NYSE: JNJ) today announced the final results of its previously announced offer to its shareholders to exchange their shares of Johnson & Johnson common stock for shares of Kenvue Inc. (NYSE: KVUE) (“Kenvue”) common stock owned by Johnson & Johnson. The exchange offer expired at 12:00 midnight, New York City time, at the end of the day on August 18, 2023.

Read more
Lilly

Lilly Completes Acquisition of Sigilon Therapeutics

INDIANAPOLIS, Aug. 14, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Sigilon Therapeutics, Inc. (NASDAQ: SGTX). The acquisition allows Lilly to continue researching and developing encapsulated cell therapies, including SIG-002, for the treatment of type 1 diabetes.

Read more
Lilly

Lilly Completes Acquisition of Versanis Bio

INDIANAPOLIS, Aug. 14, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Versanis Bio. The acquisition expands Lilly's portfolio to include Versanis' lead asset, bimagrumab, which is currently being assessed in a Phase 2b study alone and in combination with semaglutide in adults living with overweight or obesity.

Read more